What question did this study set out to answer?

The study aims to evaluate the effectiveness of HistioTrak in detecting BRAF V600E mutations and assess treatment outcomes in pediatric patients with LCH.

April 23, 2026CancersOpen Access

Expanding the Toolbox: Utility of HistioTrak for Minimal Residual Monitoring in Pediatric Patients with Langerhans Cell Histiocytosis Treated with Targeted Therapy

View Full Paper

Ask AI

Bookmark

Authors

RNRainelle NeversUniversity of North Texas ARAnusha RajbhandariUniversity of North Texas DRDevon RoemingUniversity of North Texas

Discussion

Member takes

Implication

Retrospective study finds that trametinib shows favorable outcomes in LCH, suggesting potential for improved monitoring tools.

Key Points

The study aims to evaluate the effectiveness of HistioTrak in detecting BRAF V600E mutations and assess treatment outcomes in pediatric patients with LCH.
Single-center retrospective analysis of medical records
11 pediatric patients with LCH treated with trametinib analyzed
Evaluation of HistioTrak assay for detecting BRAF V600E mutations in PBMCs.
HistioTrak identified BRAF V600E mutations in 5 patients
Trametinib treatment showed favorable short-term outcomes in all patients
Serial testing with HistioTrak was feasible in selected cases of the cohort.

Cite This Study

Nevers et al. (2026) studied this question.

synapsesocial.com/papers/69e9ba6b85696592c86ec8f8 https://doi.org/10.3390/cancers18081307

View Full Paper

Ask AI

Bookmark

Expanding the Toolbox: Utility of HistioTrak for Minimal Residual Monitoring in Pediatric Patients with Langerhans Cell Histiocytosis Treated with Targeted Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Expanding the Toolbox: Utility of HistioTrak for Minimal Residual Monitoring in Pediatric Patients with Langerhans Cell Histiocytosis Treated with Targeted Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider